An Ad5E1-, E2b-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice

Cancer Gene Therapy

Volumn 18, Issue 5, 2011, Pages 326-335

  Gabitzsch, E S ^a   Xu, Y ^a   Balcaitis, S ^a   Balint Jr , J P ^a   Jones, F R ^a  

^a Etubics Corporation   (United States)

Author keywords

Ad5; Adenovirus vector; breast cancer; HER2 neu; immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; CANCER ANTIBODY; ERBB2 PROTEIN, MOUSE; TUMOR ANTIGEN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TUMOR GROWTH; VIRUS IMMUNITY; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CYTOTOXICITY TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE VECTOR; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; SERODIAGNOSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MURINAE; MUS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VECTORS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECEPTOR, ERBB-2; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSGENES;

EID: 79954800377     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.82     Document Type: Article

References (40)

1. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679.
2. Romano G, Pacilio C, Giordano A. Gene transfer technol-ogy in therapy: current applications and future goals. Stem Cells 1999; 17: 191-202. (Pubitemid 29350210)
3. Kirk CJ, Hartigan-O'Connor D, Mule JJ. The dynamics of the T-cell anitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 2001; 61: 8794-8802. (Pubitemid 34013893)
4. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L et al. T cell-dependant antitumor immunity mediated by secondary lympoid tissue chemokine: augmentation of dendrtitic cell-based immu-notherapy. Cancer Res 2001; 61: 2062-2070. (Pubitemid 32692028)
5. Polo JM, Dubensky Jr TW. Virus-based vectors for human vaccine applications. Drug Discov Today 2002; 7: 719-727. (Pubitemid 34754378)
6. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007; 6: 255-266. (Pubitemid 46613525)
7. Gaydos CA, Gaydos JC. Adenovirus vaccine. In: Orenstein WA (eds). Vaccines, 4th edn. Sauders: Philadelphia, 2004, pp 863-885.
8. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 1998; 161: 5607-5613. (Pubitemid 28519126)
9. Diao J, Smythe JA, Smyth C, Rowe PB, Alexander IE. Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther 1999; 6: 845-853. (Pubitemid 29243659)
10. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998; 91: 392-398. (Pubitemid 28053360)
11. Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117: 244-251. (Pubitemid 29343594)
12. Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-trans-duced murine dendritic cells. Cancer Res 1997; 57: 2865-2869. (Pubitemid 27315029)
13. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25. (Pubitemid 127672232)
14. Rea D, Schagen FH, Hoeben RC, Mehtali M, Havenga MJ, Toes RE et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 1999; 73: 10245-10253.
15. Hirschowitz EA, Weaver JD, Hidalgo GE, Doherty DE. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther 2000; 7: 1112-1120. (Pubitemid 30458802)
16. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immedi-ate-early promoter in the mouse liver: involvement of NF-Kappa-B. J Virol 1998; 72: 180-190. (Pubitemid 28048827)
17. Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM, Takayama T et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-KappaB-dependent pathway. J Virol 2000; 74: 9617-9628.
18. Wan Y, Emtage P, Foley R, Carter R, Gauldie J. Murine dendritic cells transduced with an adenoviral vector expres-sing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. Int J Oncol 1999; 14: 771-776.
19. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol 2007; 81: 6594-6604. (Pubitemid 46878063)
20. Kresge KJ. Clinical trials yield promising results from two adenovirus-based vaccines. IAVI Rep 2005; 9: 24.
21. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in adult populations of The Gambia, South Africa and the United States. Clin Diagn Lab Immunol 2004; 11: 351-357. (Pubitemid 38380817)
22. Gabitzsch ES, Xu Y, Yosida L, Balint J, Amalfitano A, Jones FR et al. A preliminary and comparative evaluation of a novel Ad5[E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immuno Lett 2009; 122: 44-51.
23. Papp Z, Babiuk LA, Baca-Estrada ME. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine 1999; 17: 933-943. (Pubitemid 29074748)
24. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933. (Pubitemid 28116869)
25. Hodges BL, Serra D, Hu H, Begy CA, Chamberlain JS, Amalfitano A. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med 2000; 2: 250-259.
26. Hu H, Serra D, Amalfitano A. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999; 10: 355-364. (Pubitemid 29097314)
27. Osada T, Yang XY, Hartman ZC, Glass O, Hodges BL, Niedzwiecki D et al. Optimization of vaccine responses with an E1, E2b, E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009; 16: 673-682.
28. Everett RS, Hodges BL, Ding EY, Xu F, Serra D, Amalfitano A. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 2003; 14: 1715-1726. (Pubitemid 38010662)
29. Gabitzsch ES, Xu Y, Balint Jr JP, Hartman ZC, Lyerly HK, Jones FR. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5[E1-, E2b-]-CEA. Cancer Immunol Immunother 2010; 59: 1131-1135.
30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
31. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-112. (Pubitemid 20032452)
32. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624-2632. (Pubitemid 34575634)
33. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14: 797-803. (Pubitemid 351231162)
34. Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Amalfitano A, Jones FR. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009; 27: 6394-6398.
35. Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicity and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Research 2010; 16: 1466-1477.
36. Helguera G, Rodriguez JA, Penichet ML. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol Cancer Ther 2006; 5: 1029-1040. (Pubitemid 43724604)
37. Balint Jr JP, Jones FR. Detection of elevated levels of antiidiotypic antibody levels in immune thrombocytopenic patients expressing antiplatelet antibody. Blood 1994; 84: 664-665. (Pubitemid 24215972)
38. Carlsson G, Gullberg B, Hafstrom L. Estimation of tumor volume using different formulas\an experimental study in rats. J Cancer Res Clin Oncol 1983; 105: 20-23. (Pubitemid 13194363)
39. Appledorn DM, Kiang A, McBride A, Jiang H, Seregin S, Scott JM et al. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Ther 2008; 15: 885-901. (Pubitemid 351791476)
40. Seregin SS, Amalfitano A. Overcoming pre-existing adeno-virus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009; 9: 1521-1531.